rolipram has been researched along with Body Weight in 11 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Colitis was quantified by a clinical activity score assessing weight loss, stool consistency, and rectal bleeding (range from 0 to 4); by colon length; by a semiquantitative histologic score (range from 0 to 6); and by detecting TNF concentration in colonic tissue by enzyme-linked immunosorbent assay." | 5.31 | Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. ( Albrich, S; Bidlingmaier, C; Eigler, A; Endres, S; Hartmann, G; Lehr, HA; Schulze, J; Siegmund, B; Tschoep, K, 2000) |
| " In the present study, animals exposed to the chronic unpredictable stress (CUS), a rodent model of depression, exhibited elevated corticosterone, depressive-like behavior, memory deficits, accompanied with decreased cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling and neuroplasticity." | 3.81 | Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice. ( Li, YF; Liu, YQ; O'Donnell, JM; Wang, ZZ; Wilson, SP; Xu, Y; Yang, WX; Zhang, HT; Zhang, Y; Zhang, YZ; Zhao, N, 2015) |
| "Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction." | 1.38 | Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. ( Dong, H; Guo, L; Hammock, BD; Pinkerton, KE; Uyeminami, D; Wang, L; Yang, J, 2012) |
| "Colitis was quantified by a clinical activity score assessing weight loss, stool consistency, and rectal bleeding (range from 0 to 4); by colon length; by a semiquantitative histologic score (range from 0 to 6); and by detecting TNF concentration in colonic tissue by enzyme-linked immunosorbent assay." | 1.31 | Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. ( Albrich, S; Bidlingmaier, C; Eigler, A; Endres, S; Hartmann, G; Lehr, HA; Schulze, J; Siegmund, B; Tschoep, K, 2000) |
| "Rolipram is a selective inhibitor of Type IV phosphodiesterase isozymes (PDE IV) which is often used as a baseline comparator for compounds in this class." | 1.29 | The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. ( Geiger, LE; Larson, JL; Pino, MV; Simeone, CR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, ZZ | 1 |
| Yang, WX | 1 |
| Zhang, Y | 1 |
| Zhao, N | 1 |
| Zhang, YZ | 1 |
| Liu, YQ | 1 |
| Xu, Y | 1 |
| Wilson, SP | 1 |
| O'Donnell, JM | 1 |
| Zhang, HT | 1 |
| Li, YF | 1 |
| Vickers, SP | 1 |
| Hackett, D | 1 |
| Murray, F | 1 |
| Hutson, PH | 1 |
| Heal, DJ | 1 |
| Kenk, M | 1 |
| Thackeray, JT | 1 |
| Thorn, SL | 1 |
| Dhami, K | 1 |
| Chow, BJ | 1 |
| Ascah, KJ | 1 |
| DaSilva, JN | 1 |
| Beanlands, RS | 1 |
| Wang, L | 1 |
| Yang, J | 1 |
| Guo, L | 1 |
| Uyeminami, D | 1 |
| Dong, H | 1 |
| Hammock, BD | 1 |
| Pinkerton, KE | 1 |
| Moore, CS | 1 |
| Earl, N | 1 |
| Frenette, R | 1 |
| Styhler, A | 1 |
| Mancini, JA | 1 |
| Nicholson, DW | 1 |
| Hebb, AL | 1 |
| Owens, T | 1 |
| Robertson, GS | 1 |
| Larson, JL | 1 |
| Pino, MV | 1 |
| Geiger, LE | 1 |
| Simeone, CR | 1 |
| Waki, Y | 1 |
| Horita, T | 1 |
| Miyamoto, K | 1 |
| Ohya, K | 1 |
| Kasugai, S | 1 |
| Hartmann, G | 1 |
| Bidlingmaier, C | 1 |
| Siegmund, B | 1 |
| Albrich, S | 1 |
| Schulze, J | 1 |
| Tschoep, K | 1 |
| Eigler, A | 1 |
| Lehr, HA | 1 |
| Endres, S | 1 |
| Lamprecht, A | 1 |
| Ubrich, N | 1 |
| Yamamoto, H | 1 |
| Schäfer, U | 1 |
| Takeuchi, H | 1 |
| Maincent, P | 1 |
| Kawashima, Y | 1 |
| Lehr, CM | 1 |
| Schultz, JE | 2 |
| Rösch, H | 1 |
| Schmidt, BH | 1 |
11 other studies available for rolipram and Body Weight
| Article | Year |
|---|---|
Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Topics: Animals; Body Weight; Corticosterone; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cycli | 2015 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Mo | 2015 |
Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Cyclic AMP; Doxorubicin; Echocardiography; Ephedr | 2010 |
Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.
Topics: Animals; Benzoates; Body Weight; Bronchoalveolar Lavage Fluid; Cytokines; Enzyme Inhibitors; Epoxide | 2012 |
Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Cyclic Nucleotide Phosphodiesterases, Typ | 2006 |
The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats.
Topics: Animals; Blood Vessels; Body Weight; Eating; Female; Liver; Myocardium; Necrosis; Organ Size; Phosph | 1996 |
Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Bone Density | 1999 |
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
Topics: Animals; Body Weight; Colitis; Dextran Sulfate; Feces; Female; Hemorrhage; In Vitro Techniques; Mice | 2000 |
Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Colon; Drug Carriers; Drug Delivery S | 2001 |
Differential effects of ovarian steroid hormones on beta-adrenoceptor downregulation caused by the antidepressants imipramine and rolipram.
Topics: Animals; Antidepressive Agents; Body Weight; Cerebral Cortex; Down-Regulation; Estrone; Female; Gona | 1991 |
Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes beta-adrenoceptor subsensitivity in rat cerebral cortex.
Topics: Adenylyl Cyclases; Animals; Body Weight; Cerebral Cortex; Cyclic AMP; Hydroxydopamines; Male; Norepi | 1986 |